EU updates note on issuing duplicate drug marketing authorisations
This article was originally published in SRA
Executive Summary
The European Commission has issued a revised note on how it handles requests from pharmaceutical companies for duplicate marketing authorisations1,2. The revised note, among other things, attempts to clarify a misunderstanding by applicants of the term "true duplicate" in the March 2010 version of the document3,4.
You may also be interested in...
EU Proposal To Address Impact Of Duplicate Marketing Authorizations On Biosimilars Availability
The European Commission has proposed updating its guidance on duplicate marketing authorizations to address concerns regarding the availability of biosimilars.
EU Proposal To Address Impact Of Duplicate Marketing Authorizations On Biosimilars Availability
The European Commission has proposed updating its guidance on duplicate marketing authorizations to address concerns regarding the availability of biosimilars.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.